Previous Article | Next Article 
Journal of Virology, April 2001, p. 3095-3104, Vol. 75, No. 7
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.7.3095-3104.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Target Distinct Phases of Early Reverse
Transcription
C. William
Hooker,1,2,3
William
B.
Lott,1,3 and
David
Harrich1,2,3,*
HIV-1 and Hepatitis C Units, Sir Albert
Sakzewski Virus Research Centre, Royal Children's Hospital,
Herston,1 and Australian National Centre
in HIV Virology Research2 and CMVC,
University of Queenland,3 St. Lucia,
Queensland, Australia
Received 25 August 2000/Accepted 5 January 2001
 |
ABSTRACT |
Early HIV-1 reverse transcription can be separated into initiation
and elongation phases. Here we show, using PCR analysis of
negative-strand strong-stop DNA [(
)ssDNA] synthesis in intact virus, that different reverse transcriptase (RT) inhibitors affect distinct phases of early natural endogenous reverse transcription (NERT). The effects of nevirapine on NERT were consistent with a
mechanism of action including both specific and nonspecific binding
events. The nonspecific component of this inhibition targeted the
elongation reaction, whereas the specific effect seemed principally to
be directed at very early events (initiation or the
initiation-elongation switch). In contrast, foscarnet and the
nucleoside analog ddATP inhibited both early and late (
)ssDNA
synthesis in a similar manner. We also examined compounds that targeted
other viral proteins and found that Ro24-7429 (a Tat antagonist) and
rosmarinic acid (an integrase inhibitor) also directly inhibited RT.
Our results indicate that NERT can be used to identify and evaluate
compounds that directly target the reverse transcription complex.
 |
INTRODUCTION |
Human immunodeficiency virus type 1 (HIV-1), like all retroviruses, uses a virally encoded reverse
transcriptase (RT) to convert its positive-strand RNA genome into
double-stranded DNA (2, 56). Synthesis of the first
product of reverse transcription, 181 nucleotides (nt) of
single-stranded DNA called negative-strand strong-stop DNA
[(
)ssDNA], is subject to complex regulation by both cellular and
viral factors. A ribonucleoprotein complex composed of (at least) RT
and a cell-derived tRNA
molecule initiates reverse
transcription from the primer binding site (PBS) (54), an
18-nt viral genomic sequence complementary to the 3' end of
tRNA
. A specific reverse transcription initiation
complex (RTIC) is thought to form as a result of intrastrand base
pairing between the viral A-rich loop sequences located upstream of the
PBS and the tRNA
anticodon loop sequences, together
with intermolecular interactions between
tRNA
, RT, and viral genomic RNA (23,
25).
Many viral factors, including Nef (1), Vif (12, 51,
61), matrix protein (MA) (28), nucleocapsid protein
(NCp7) (36, 49), integrase (IN) (40, 66), and
Tat (17), affect the efficiency of reverse transcription.
Viruses mutated or deleted in the nef, vif, or
matrix genes showed decreased reverse transcription efficiency as a result of defective virus formation and/or postentry capsid uncoating. NCp7 greatly facilitates strand transfer and reduced
pausing of RT at RNA stem-loop structures during reverse transcription
(14, 26). Viruses lacking IN or Tat are defective for
initiation of reverse transcription, but this defect can be rescued by
trans complementation in the virus-infected cell (60, 66). Analysis of mutated IN and tat genes
has shown that their roles in reverse transcription are distinct from
their other well-characterized roles in virus replication, but the
mechanisms by which IN and Tat affect reverse transcription are not known.
Lanchy et al. (34) and Thrall et al. (57)
have described the kinetics of HIV-1 reverse transcription. A general
mechanism of DNA synthesis by RT includes binding of RT to the
template, binding of the appropriate nucleotide, chemical synthesis
(phosphodiester bond formation), and release of pyrophosphate.
Pre-steady-state kinetic measurements indicate that the rate-limiting
step during the incorporation of a single nucleotide is the
conformational change of the RT complex from an inactive to an
active form (63), which precedes covalent bond
synthesis. In addition, the RTIC, which forms around an
RNA-RNA duplex, must alter its conformation to accommodate
RNA-DNA hybrids during RNA-dependent synthesis of (
)ssDNA
(27). The requirement for a conformational change in
RT and the contacts in the narrow minor groove around the DNA-tRNA junction are major factors responsible for early (+1 to +5) pause sites
observed in reverse transcription in vitro (reviewed in reference
13). Virion-derived tRNA
placed on the RNA genome is found both in an unextended form and with the
first two bases of (
)ssDNA added (22), suggesting that reverse transcription initiation is somehow restricted in intact viruses obtained from tissue culture supernatants. In other respects, DNA synthesis by HIV-1 RT is kinetically similar to the actions of
other polymerases, although HIV-1 RT is particularly susceptible to pausing caused by RNA stem-loop structures that can dislodge it from the template (9, 18, 34, 55).
Intact HIV-1 can carry out reverse transcription of at least part of
its genome in physiological milieux, without the mild detergent
treatment used to permeabilize virions in classical endogenous reverse
transcription (ERT) assays (39, 58). Intravirion DNA
synthesis in the absence of permeabilizing agents has been termed
natural ERT (NERT) to distinguish it from the somewhat artificial
process which takes place in standard ERT assays (69). NERT is made possible by the amphipathic domains of the gp41
transmembrane protein, which render the HIV-1 envelope permeable to a
range of small molecules (68). In vivo, NERT is an active
process which is responsive to the virion microenvironment. Virus
isolated from seminal plasma, which contains high levels of
deoxynucleoside triphosphates (dNTPs), contained much higher levels of
full-length or nearly full-length intravirion reverse transcripts than
did virus isolated from the blood of the same patients
(69). Moreover, the ability of purified virions to infect
initially quiescent T cells and nonproliferating cells such as
macrophages was significantly increased by preincubation of the virions
with seminal plasma (69), indicating that NERT may be an
integral part of the viral life cycle and play an important role in the
infection of nondividing cells. NERT is also susceptible to inhibition
in vivo: the levels of intravirion reverse transcripts in virus
isolated from the blood of HIV-infected patients dropped dramatically
after commencement of nevirapine (NVP) therapy and rebounded to
pretreatment levels concomitant with the development of NVP resistance
in the virus (70). Virion infectivity also decreased
dramatically in response to NVP therapy and returned almost to
pretreatment levels with the development of NVP resistance
(70), indicating that the antiviral effects of NVP begin
with cell-free virions.
In the present study, we used a PCR-based assay to measure NERT in
order to investigate the effects of RT inhibitors on early reverse
transcription in intact virions. Compounds that target RT, Tat, or IN
were tested for their ability to inhibit both NERT and the activity of
recombinant HIV-1 RT in vitro. Our data indicate that although all of
the compounds tested, including those with anti-Tat and anti-IN
activities, could directly inhibit RT, their effect on early and late
(
)ssDNA synthesis produced strikingly different inhibition profiles.
Analysis of the relationship between inhibition and drug concentration
showed that nucleotide or pyrophosphate (PPi) analogs had
similar effects on both early and late (
)ssDNA synthesis, a pattern
consistent with inhibition of the elongation reaction. In contrast,
nonnucleoside inhibitors of RT had different effects on early and late
(
)ssDNA synthesis, which were consistent with inhibition of very
early reverse transcription, the most likely targets being initiation
or early pausing associated with the transition to elongation
(24, 37). Since the use of intact virus preserves all of
the viral and cellular factors that contribute to efficient reverse
transcription, these results demonstrate the utility of the NERT-PCR
assay as a probe to examine the mechanisms of drug action and to
identify novel antiretroviral compounds with unique mechanisms of action.
 |
MATERIALS AND METHODS |
Cells and virus.
Virus was grown in stably transfected 293 cells and Jurkat T cells. The isolation and characterization of a 293 cell line stably transfected with wild-type (HXB2-neo) HIV-1 is
described elsewhere (16). 293 cells were cultured in
Iscove's modified Dulbecco's medium supplemented with 5% newborn
calf serum, 2% fetal bovine serum, 1% penicillin-streptomycin
(pen/strep; Life Technologies), and 0.5 mg of Geneticin per ml. Jurkat
cells were grown in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 1% pen/strep, and 1 mg of Geneticin per ml. Cell culture
supernatants were filtered through polyethersulfone membranes with a
pore size of 0.45 µm (Nalgene) and stored in aliquots at
80°C for
use as virus stocks. Aliquots were used only once after thawing, and the stocks were not stored for more than 6 months.
Drugs.
Phosphonoformic acid (PFA; foscarnet),
phosphonoacetic acid (PAA), ddATP, ddTTP, rosmarinic acid (RA), and
curcumin were purchased from Sigma Aldrich (Sydney, Australia). The
benzodiazepins Ro 5-3335 (Ro5) and Ro 24-7429 (Ro24) were kindly
provided by Roche Products. NVP was obtained from commercial drug
preparations (Viramune, 200 mg; Boehringer, Ingelheim, Germany).
NERT assay.
Virus stocks were assayed for total RT activity
on a synthetic homopolymer template in the presence of detergent, using
a commercial enzyme-linked immunosorbent assay (ELISA) kit (Roche) as
specified by the manufacturer. Aliquots of virus (typically 0.25 mU of
RT) were incubated for 30 to 60 min at 37°C, with or without
inhibitors, in a final volume of 100 µl of Iscove's modified Dulbecco's medium supplemented with 50 U of DNase I (Worthington Biochemical) and 10 mM MgCl2. Enzymatic activity was then
terminated in controls by the addition of 150 µl of stop solution (10 mM Tris-HCl [pH 7.4], 10 mM EDTA, 20 µg of sheared salmon sperm DNA per ml, 50 µg of proteinase K per ml) followed by incubation for 10 min at 37°C and then a further 10 min in a boiling-water bath. The
remaining assay mixtures were supplemented with 200 µM dNTPs and
incubated at 37°C for 90 min, and the reactions were then terminated
as described above. Samples of each stopped reaction mixture were
serially diluted in twofold steps, and each dilution was assayed for
HIV-1 DNA by quantitative PCR using combinations of the following
HIV-1-specific oligonucleotides (Fig. 1):
S1 (5'-CAA GTA GTG TGT GCC CGT CTG TT-3'), P1 (5'-TAG
AGA TCC CTC AGA CCC TTT-3'), P2 (5'-CTG CTA GAG ATT TTT CCA
CAC TGA C-3'), D1 (5'-GGT CTC TCT GGT TAG ACC A-3'),
and D2 (5'-AAG CAG TGG GTT CCC TAG TT AG-3'). One
primer in each pair was labeled with 32P using T4
polynucleotide kinase, and the reaction products were resolved on 6%
polyacrylamide-Tris-borate-EDTA (TBE) gels and detected using a
PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.). PhosphorImager
data were analyzed with ImageQuant software (Molecular Dynamics). PCR
standard curves were generated using proviral plasmid DNA serially
diluted in mock stop solution containing MgCl2 (MMS) (6 mM
Tris-HCl [pH 7.4], 6 mM EDTA, 12 µg of sheared salmon sperm DNA per
ml, 4 mM MgCl2), and samples were diluted in MMS to keep
all signals within the linear range of the assay (approximately 75 to
2,500 copies). At least two (typically three or four) dilutions of
every sample were assayed, and data sets in which the linear
correlation coefficient of the standard curve was less than 0.98 were
not included in further analysis.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic of the PCR strategy to detect and quantitate
( )ssDNA. Regions corresponding to R (+1 to +97) and U5 (+98 to +181)
were detected by PCR using oligonucleotide probes as shown. Probes were
used to detect and quantitate different regions of ( )ssDNA designated
proximal (oligonucleotides P1 and P2, nt +132 to +181), intermediate
(oligonucleotides S1 and P2, nt +96 to +181), and distal
(oligonucleotides D1 and D2, nt +1 to +64) according to their positions
relative to the site of reverse transcription initiation. The site of
initiation and the direction of DNA synthesis by RT are indicated by
the bent arrow.
|
|
 |
RESULTS |
NERT.
Intact virus was incubated with 200 µM total dNTPs for
90 min at 37°C in the presence of DNase I, and the reactions were
terminated by EDTA addition and boiling. Reverse transcription products
were detected by PCR using oligonucleotides specific for early,
intermediate, or late (
)ssDNA (Fig. 1, probes P1 and P2, S1 and P2,
and D1 and D2, respectively). The products of these PCRs were separated on polyacrylamide gels and analyzed on a PhosphorImager. Virions incubated without dNTPs did not synthesize appreciable levels of
(
)ssDNA, and (
)ssDNA levels increased roughly proportionally with
increasing virus and dNTP concentrations (Fig. 2B). The amount of
(
)ssDNA detected in NERT-PCR assays reached ~20% of maximum in the
first 5 min and then increased in an almost linear fashion during the
first 180 min (Fig. 2A). This long
temporal linear range may be due to complex differences within the
virus population, such as differences in virion maturity. Control PCR
using a plasmid containing the target DNA sequences demonstrated that
the PCR response was linear over a 32-fold range (Fig. 2C).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Characterization of the NERT-PCR assay. (A) Virus
supernatants containing 0.25 mU of total RT activity were incubated
with 200 µM total dNTPs at 37°C for the indicated times and assayed
for ( )ssDNA by PCR using both proximal (P1 and P2) and distal
(D1 and D2 [not shown]) primer pairs (Fig. 1). NERT reaction
mixtures were serially diluted, where necessary, to conform to the
linear range of the PCR assay. All experiments were performed at least
three times with similar results, and results of representative
experiments are shown. (B) NERT assays were carried out using 200 µM
total dNTPs and increasing quantities of virus supernatant (0.1, 0.2, 0.4, and 0.8 mU of RT activity, measured using a commercial
homopolymer template RT assay), or using virus supernatants containing
0.25 mU of RT activity and increasing total concentrations of
dNTPs (0, 5, 10, 50, 100, 250, 500, and 1000 µM); these assay
mixtures were incubated for 90 min at 37°C, and ( )ssDNA was
measured using primers P1 and P2 (Fig. 1). (C) Analysis of control
DNAs, used to quantify the PCR results (r2 = 0.998).
|
|
Effects of nucleoside and nonnucleoside RT inhibitors on NERT.
We tested the effects on (
)ssDNA synthesis by NERT of various reverse
transcriptase inhibitors, including PAA, PFA, NVP, ddATP, and ddTTP
(Fig. 3). These compounds were selected
to represent a range of different mechanisms of RT inhibition. The
PPi analog PFA inhibits RT by occupying the PPi
binding pocket (7, 43). NVP is a specific noncompetitive
inhibitor of RT that can bind directly to a hydrophobic pocket within
the enzyme (31), causing a conformational change that
disrupts the catalytic site and blocks its DNA polymerase activity.
Both ddATP and ddTTP are nucleoside analogs which, when incorporated
into a nascent DNA chain by RT, result in the termination of DNA
synthesis. PAA, which is structurally closely related to PFA, had no
effect on NERT even at millimolar concentrations. In contrast, PFA at
60 and 160 µM decreased total (
)ssDNA levels (measured using PCR
probes S1 and P2) by 75% and by more than 98%, respectively, compared
to uninhibited virus. NVP at 10 to 50 µM inhibited NERT to a similar
degree, in agreement with studies of virus isolated from patients
taking NVP (67). Both ddATP at 10 µM and ddTTP at 50 µM also effectively inhibited NERT. All of the observed reductions in
PCR signals could be attributed to inhibition of NERT, since none of
the drugs tested showed any inhibitory activity against Taq
DNA polymerase (Fig. 3B). We also compared the effects of the various
drugs in our NERT-PCR assay to their effects in a commercial reverse
transcriptase ELISA (Table 1). In
general, the two assays showed similar results, although some compounds
were more effective against in vitro reverse transcription on a
homopolymer template by recombinant HIV-1 RT than against NERT in
intact virions. This observation may reflect the different nucleotide
concentrations used in each assay, particularly with respect to
nucleoside analog inhibitors, and/or the effect of membrane
permeability on intravirion drug concentration.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 3.
NERT is inhibited by nucleoside analogs and
nonnucleoside RT inhibitors. (A) NERT reaction mixtures containing 0.25 mU of virion RT activity were preincubated for 30 min with RT
inhibitors (PAA, PFA, NVP, ddATP, and ddTTP) at the concentrations
indicated (micromolar), or with dimethyl sulfoxide (DMSO) (solvent
vehicle for NVP). Then 200 µM dNTP was added to each NERT reaction
mixture except as indicated (panel A, -dNTP), and all the mixtures were
incubated at 37°C for 90 min. The reactions were terminated, and the
products were assayed for ( )ssDNA by PCR using primers P1 and P2
(Fig. 1). (B) RT inhibitors or DMSO was added to PCR mixtures
containing 1,000 copies of proviral plasmid DNA at concentrations
slightly higher than were carried over from any of the corresponding
NERT assays. All PCR results were within the linear range of the assay
(r2 > 0.99). Experiments were performed at
least three times, and typical results are shown.
|
|
Tat and IN inhibitors down regulate NERT.
Previous studies
have shown that the drugs Ro24 and Ro5 inhibit Tat-induced HIV-1 gene
expression (20). Since Tat plays a role in reverse
transcription, we tested the effects of these Tat antagonists on NERT
(Fig. 4) and on recombinant RT in vitro (Table 1). Ro24 decreased (
)ssDNA synthesis in NERT assays (measured using PCR probes S1 and P2) by ~55% at 200 µM and inhibited
recombinant RT activity in vitro by ~60 and ~85% at 25 and 250 µM, respectively. It therefore appeared that the observed inhibition
of NERT by Ro24 was mediated by direct activity against RT and was
unrelated to Tat antagonist activity. Ro5 had no effect on NERT and
little effect on recombinant RT in vitro (less than 20% inhibition at 250 µM).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 4.
NERT is inhibited by anti-Tat and anti-IN compounds. (A
and B) NERT reaction mixtures containing 0.25 mU of virion RT activity
were preincubated for 30 min with solvent (DMSO) or with Ro24, Ro5, RA,
or curcumin at the concentrations indicated (micromolar). The reaction
mixtures were supplemented with 200 µM dNTP, except as indicated
(panel A, -dNTP) and incubated at 37°C for 90 min, the reactions were
terminated, and the products were assayed for ( )ssDNA by PCR using
primers P1 and P2 (Fig. 1). (C) RT inhibitors or DMSO was added to PCR
mixtures containing 1,000 copies of proviral plasmid DNA at
concentrations slightly higher than were carried over from any of the
corresponding NERT assays. All PCR results were within the linear range
of the assay (r2 > 0.99). Experiments were
performed at least three times, and typical results are shown.
|
|
Like Tat, HIV-1 IN plays a role in reverse transcription which is
separate from its eponymous role (
66). We therefore tested
the effects on reverse transcription of two related IN inhibitors,
curcumin and RA (Fig.
4; Table
1). In in vitro assays of IN activity,
the 50% inhibitory concentration of RA is ~15-fold lower against
3'-processing activity and ~35-fold lower against strand transfer
activity than the 50% inhibitory concentration of curcumin
(
41).
RA inhibited the activity of both NERT and
recombinant HIV-1 RT
in commercial ELISAs by ~30 to 40% at 100 µM
and by ~50 to 60%
at 200 µM. This indicates that the effect of RA
on NERT is probably
attributable to direct inhibition of RT. We also
found that Moloney
murine leukemia virus (M-MLV) RT, in a standard RT
assay using
homopolymer template and primer, was inhibited by high (200 µM)
but not by low (

50 µM) concentrations of RA (data not shown).
Curcumin inhibited recombinant RT by only ~30% at 100 and 200
µM
and had no effect on
NERT.
RT inhibitors display differential inhibition of proximal and
distal (
)ssDNA synthesis.
Next, we modified the PCR step in the
NERT-PCR assay to distinguish between early and late (
)ssDNA
synthesis. We assayed NERT DNA products over two short regions proximal
(Fig. 1, probes P1 and P2) and distal (Fig. 1, probes D1 and D2) to the
PBS and compared the levels of proximal and distal DNA generated by
wild-type virus in the presence of increasing concentrations of various RT inhibitors. At least three serial dilutions of each NERT reaction mixture were assayed by PCR, and at least two dilutions with signals that were within the linear range of the assay were used to generate each data point. Only data sets for which the standard curve showed a
correlation coefficient (r2) greater than 0.98 were included in the final analyses. The relative levels of proximal
and distal DNA observed in the absence of drug varied between virus
stocks, with distal DNA copy numbers ranging from 30 to 50% of
proximal DNA copy numbers (Table 2). This
intrinsic termination has not been previously described in NERT or any
other system, but several studies have observed that HIV-1 RT is
susceptible to pausing along adenosine-rich RNA sequences or at stable
RNA secondary structures (9, 18, 34, 55). As expected,
increasing concentrations of inhibitor resulted in increased total
inhibition of (
)ssDNA, with the greatest inhibitory effect on distal
DNA levels. Table 2 shows representative data for ddATP and NVP; PFA
and RA gave similar total inhibition patterns, and four to six separate
experiments with each compound gave simular results (data not shown).
It is clear from these observations that there exists an intrinsic
termination rate (ITR =
d0/
p0, where
d0 is the distal copy
number in the absence of
drug [0 µM drug] and
p0 is the proximal
copy
number in the absence of drug [0 µM drug]), which describes
premature termination in the absence of an inhibitor and must
be taken
into account in order to calculate the degree of inhibition
of the
distal signal that can be attributed to drug action. We
defined the
expected distal value (edv
n =
pn × ITR, where
edv
n is
the expected distal copy number at a given drug
concentration
[
n µM drug] and
pn is the
proximal copy number at
a given drug concentration [
n µM
drug]) as the distal copy number
that would be expected in the absence
of any drug-related termination.
This value can then be used to define
the percent inhibition of
the distal signal which is due to drug
activity [%
D = 100(1
dn/edv
n), where
dn is the distal copy number at a given
drug
concentration (
n µM drug)]. Plots of the percent
inhibition
of the proximal signal [%
P = 100 (1
pn/
p0)] and
%
D against drug
concentration (inhibition curves)
revealed differences between
the anti-RT compounds tested (Fig.
5). The inhibitors were examined
over
concentration ranges which resulted in similar total levels
of inhibition [%
T = 100(1
dn/
p0)] of NERT, from
~70 to 98%.
The proximal and distal inhibition curves of both PFA
and ddATP
showed a regular hyperbolic concentration dependence
consistent
with a single binding site {
I =
Imax [
c/(
c +
kd)], where
I is
the percent
inhibition [%
P or %
D],
Imax is the maximal percent
inhibition expressed
as a percentage,
c is the micromolar drug
concentration and
kd is the micromolar dissociation
coefficient}.
Regression analysis showed that the PFA and ddATP
inhibition curves
fit this expression with correlation coefficients
(
r2) of ~0.98 to 0.99 in all cases. Consistent
with its known activity
as an inhibitor of the RT elongation reaction,
ddATP effected
greater inhibition of late than of early DNA synthesis
(Fig.
5A).
A similar but even more marked effect was observed for PFA:
maximal
inhibition (
Imax) of ddATP proximal and
distal inhibition curves
and of PFA distal inhibition curves was
approximately 100%, but
Imax of PFA proximal
inhibition curves ranged from 50 to 70% in
five independent assays
(Fig.
5B and data not shown). These data
distinguish the effects of PFA
from inhibition by dideoxynucleotides
and suggest that PFA is a
relatively weak inhibitor of RT which
requires many rounds of
nucleotide addition to achieve complete
termination of reverse
transcription.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 5.
NERT inhibition curves for nucleoside analogs and
nonnucleoside compounds. (A to D) NERT assays were carried out in the
presence of increasing concentrations of four different inhibitors:
ddATP at 0.25, 0.5, 1, 2, 4, and 8 µM (A); PFA at 3, 6, 9, 12, 15, and 18 µM (B); NVP at 0.25, 0.5, 1, 2, 4, and 6 µM (C); and RA at
10, 25, 50, 100, and 200 µM (D). Each NERT reaction product was
assayed for ( )ssDNA by PCR using either the proximal (P1 and P2) or
the distal (D1 and D2) DNA primer pair (Fig. 1). Total inhibition
(%T; dotted line, solid circles), proximal inhibition
(%P; dotted line, open circles), and distal inhibition
(%D; solid line, open squares) were calculated and plotted
against drug concentrations. All of the proximal inhibition curves
were accurately described by regular hyperbolic expressions (see the
text), as were the distal inhibition curves for ddATP and PFA. The
expression which best fit the NVP distal inhibition curve, however,
included an additional component describing nonspecific interaction
(see the text). (E) The specific (hyperbolic, dashed line) and
nonspecific (linear, dotted line) components of the NVP distal
inhibition curve (solid line, open squares). Three to five independent
experiments were performed with each drug, and representative results
are shown.
|
|
NVP concentrations as low as 0.25 µM inhibited reverse transcription
by more than 80%, and ~95% inhibition was observed at
NVP
concentrations of 4 µM or higher (%
T [Fig.
5C; Table
2]).
Like ddATP and PFA, NVP proximal inhibition curves were
accurately
(
r2 > 0.99 for two separate
experiments and ~0.96 for a third data
set) described by a hyperbolic
binding curve, suggesting a single
binding site (see above). In
contrast, NVP distal curves were
most accurately
(
r2 > 0.99 in all cases) described by the
addition of an expression
describing nonspecific inhibition
{
I =
Imax
[c/(
c +
kd)] +
mc,
where
m is a nonspecific inhibition
coefficient} (Fig.
5E). The
nonspecific component was most apparent
at concentrations of NVP
(1 to 8 µM) sufficient to saturate the
well-characterized hydrophobic
binding pocket
(
kd = 0.025 µM) which is believed to mediate
the
specific effect of NVP (
53), suggesting that the
nonspecific
inhibition does not involve this site. The nonspecific
component
was not apparent in the proximal data, probably because
primer
P1 is less than 60 bp from the PBS: the observed effect of
nonspecific
interference with NERT would be expected to increase with
distance
from the PBS. Whereas NVP proximal-inhibition curves showed
maximal
theoretical inhibition levels (
Imax) of
80 to 90% in each of five
different experiments (Fig.
5 and data not
shown), the
Imax of
the portion of distal
inhibition which was described by a regular
hyperbolic expression (see
above) was only 30 to 40% (Fig.
5E,
dashed line). These experiments
suggest that in NERT, the elongation
reaction is somewhat resistant to
inhibition by NVP. For example,
NVP at 0.5 µM inhibited proximal DNA
synthesis by ~50%, but drug
action inhibited further DNA synthesis
by only ~33%. In other
words, once proximal DNA was completed,
~33% of the elongation
reactions was further inhibited by NVP (Fig.
5C). Both ddATP and
PFA had much greater downstream effects, inhibiting
further DNA
synthesis by ~67 and ~86%, respectively, at
concentrations resulting
in ~50% inhibition of proximal DNA
synthesis (Fig.
5A and B).
A single binding event which affected
elongation would be expected
to result in greater inhibition of late
than of early (

)ssDNA
synthesis, as was observed in ddATP and
PFA inhibition curves.
The two hyperbolic NVP inhibition curves
(proximal and distal
specific) therefore appear to represent different
inhibitory effects
and are consistent with a model in which NVP exerts
a strong inhibitory
effect on very early events (initiation or the
initiation-elongation
switch) and a weaker effect on the elongation
reaction, in addition
to nonspecific interference with enzyme
activity.
The level of inhibition of NERT by RA, whose described antiviral target
is HIV-1 IN, was lower than that observed for the
other RT inhibitors
(Fig.
5D, %
T). Total NERT inhibition (%
T)
was
75 and 98% at 50 and 200 µM RA, respectively. Inhibition of
proximal
DNA synthesis showed hyperbolic concentration dependence
(see above),
with
Imax values of 87 and 91% in two
independent
assays (
r2 = 0.99) and 73% in
a third assay (
r2 = 0.97). RA at
concentrations up to 50 µM inhibited proximal
DNA synthesis by up to
40% but had no additional inhibitory effect
on distal DNA synthesis
(indicating that these concentrations
of RA did not affect the RT
elongation reaction) in three independent
assays. In two other assays,
however, we observed up to 20% inhibition
of distal DNA synthesis in
addition to the proximal inhibition.
Higher concentrations of RA caused
variable levels of inhibition,
but 200 µM RA inhibited distal DNA
synthesis by 86 to 100% in
five independent NERT-PCR assays, and this
concentration of RA
also inhibited Moloney murine leukemia virus RT in
a standard
RT assay using homopolymer template and primer (data
not shown).
These results are similar to those observed for NVP
and indicate
that RT which completed proximal (

)ssDNA was nearly
resistant
to further inhibition by RA at concentrations up to 50 µM.
While
these experiments cannot precisely map termination, the data are
consistent with direct inhibition of either reverse transcription
initiation or the switch to
elongation.
 |
DISCUSSION |
DNA synthesized within intact HIV-1 virions is the product of
partial reverse transcription that can be influenced by physiological environments (39, 58). For example, seminal fluid, which
contains high levels of dNTPs, stimulates negative-strand DNA
synthesis, while virus isolated from infected patients taking NVP
contains diminished levels of intravirion DNA compared to virus
obtained before therapy (69, 70). In the present study, we
used a quantitative NERT-PCR assay that directly measured the effects
of RT inhibitors on early reverse transcription in intact virus
particles. We have provided experimental evidence, for the first time
using intact virus, that both NVP and RA (a previously identified HIV-1
IN inhibitor) can inhibit very early reverse transcription, with the
most likely targets being initiation or the switch from initiation to elongation.
In the present study, we have not examined whether the effects of NVP
and RA during NERT are identical to the effects of these drugs during
cell infections by HIV-1. Difficulties in accurately controlling the
many additional variables in a cellular system, particularly
intracellular concentrations of RT inhibitors, render such experiments
technically difficult, especially with respect to detailed analysis of
inhibitory effects on early and late (
)ssDNA synthesis. Others have
shown, however, that endogenous RT assays can accurately reveal
synergies of drug-resistant RT genotypes previously observed in vivo
(8, 45). Our comparisons of reverse transcription
initiation defects observed in viruses carrying mutations in either the
tat gene (60) or the TAR RNA element (15) have demonstrated that NERT provides an accurate
model of early reverse transcription.
Biochemical analysis of in vitro reverse transcription has shown that
the initiation of reverse transcription can be distinguished from the
subsequent elongation reaction (24, 33). Initiation of
reverse transcription is regulated by complex interactions between the
cellular tRNA
, RT (3, 44), NCp7
(35, 36), and the RNA genome containing the PBS and
3'-flanking RNA sequences, U5 (21, 23), and the TAR RNA
element (6, 15). The initiation reaction is characterized
by early pausing (18, 29, 33), which is more prominent at
low concentrations of dNTPs (37), so that reverse
transcription elongation appears to be induced under conditions that
favor the completion of proviral DNA synthesis. NVP, which binds within
a hydrophobic pocket near the catalytic site of RT (32),
inhibits the initial "burst" of polymerization in vitro
(53); in the presence of bound NVP, dNTPs bind tightly but
nonproductively to RT, resulting in a decreased rate of polymerization.
In the present study, we compared the effects of different antiviral
compounds on (
)ssDNA synthesis in intact virus. Induction of reverse
transcription with 200 µM dNTP in the absence of any inhibitors
revealed a high level of intrinsic termination, ranging from 50 to 70%
in different virus stocks. To our knowledge, this phenomenon has not
been previously described. Pause sites in (
)ssDNA have been mapped in
vitro and are enhanced at adenosine-rich RNA regions (18)
and stable RNA stem-loop structures (65), such as the TAR
element and the poly(A) stem-loop (29), that can dislodge
RT from the RNA template. Less efficient elongation in NERT could be
due to several reasons, such as a postinitiation reorganization of the
genomic RNA-tRNA
complex, uncoating, or other
viral and cellular factors. While others have shown that
truncated (
)ssDNA can complete the first strand jump of reverse
transcription, the efficiency of such strand transfers is reduced
relative to that of transfers involving full-length or near-full-length
(
)ssDNA (30, 38, 46, 64). Together, these observations
suggest that postentry events are probably required for optimal
(
)ssDNA synthesis and complete reverse transcription.
As might be expected of RT elongation inhibitors, the nucleoside analog
ddATP and the PP; analog PFA both effected greater inhibition of distal
DNA synthesis than of synthesis near the reverse transcription
initiation site. In contrast, portions of the inhibition curves for
both NVP and RA showed greater effects at or near the initiation site
than downstream. RA exhibited little or no inhibition of distal DNA
synthesis (in excess of the inhibitory effect observed on proximal DNA)
at concentrations up to 50 µM. The specific effect of NVP on distal
DNA synthesis was relatively weak and appeared to reflect a different
inhibitory effect from that which was evident in NVP proximal
inhibition curves. These results are consistent with inhibition of very
early events in NERT, such as reverse transcription initiation or the
switch from initiation to elongation, and suggest that both RA and NVP
act on targets within the RTIC. Binding of NVP to RT is known to induce conformational change in the enzyme (32) in addition to
inhibiting the elongation reaction (52). This
conformational change may also reduce the ability of RT to function
within the RTIC. Recently, it was shown that zidovudine (AZT), a known
elongation inhibitor, has different inhibitory effects on initiation
and elongation reactions (48). This was attributed to an
apparent resistance to removal of incorporated AZT by
pyrophosphorolysis during the initiation, but not the elongation,
reaction. Our data suggest that NVP and RA also have distinct
inhibitory effects during these phases of reverse transcription.
In these experiments, nonspecific inhibition of the elongation reaction
by NVP, which has not been previously described, was observed in five
of five independent NERT assays. The inhibition of distal DNA synthesis
by NVP (Fig. 5C) gave a characteristic concentration dependence
pattern, a regular hyperbolic binding curve on a sloping baseline, that
has been previously observed (reviewed in reference 62).
When mathematically separated, the nonspecific component is represented
by a straight line that passes through zero and the remaining curve is
a regular hyperbola (Fig. 5E). Inhibition of proximal DNA
synthesis by NVP probably arises from the binding of NVP to the
previously characterized hydrophobic binding pocket adjacent to the
active site of RT (32, 47). The noncompetitive,
specific proximal inhibition never reached 100%
(Imax < 90%), indicating that the
nonspecific mechanism described here contributes significantly to the
total inhibition by NVP during NERT, particularly at concentrations
above the kd of the known binding site. It is
possible that NVP increased the intrinsic termination rate in NERT
reactions. NVP does not block nucleotide binding to RT but makes this
an unproductive event that could lead to increased pausing
(53). Such a mechanism may in fact account for the
relatively weak (Imax = 30 to
40%) specific component of distal inhibition, but the mechanism
underlying the nonspecific component remains unclear and is the subject
of a new investigation.
The nature of the RTIC is not fully understood. Many viral factors
affect reverse transcription; Nef (1, 50) and Vif (11, 12, 42, 51) seem to affect reverse transcription during virus particle formation or uncoating or by affecting RNA structure (10, 71), while IN (40, 59, 66) and
Tat (17, 60) are required for efficient initiation of
reverse transcription, and NCp7 greatly increases the efficiency of the
initiation reaction (36, 49) and improves transcript
elongation by destabilizing RNA secondary structures (14,
26). Following entry into the cytoplasm, a number of viral
proteins including MA, Vpr, IN, and RT form large, dynamic
nucleoprotein complexes that carry out reverse transcription and direct
the nuclear import of the newly synthesized provirus (5,
19). Whether these or other factors cooperate in an RTIC, which
may be distinct from an elongation complex, is under investigation. For
example, virus lacking the Tat protein (
tat) shows no obvious
structural or biochemical defects but is defective (relative to
wild-type virus) for early (
)ssDNA synthesis by NERT
(17). Interestingly, Ro24, which has been reported to
inhibit transactivation by Tat of RNA polymerase II-mediated
transcription (4, 20), directly inhibited RT in the
present study. Recent studies revealed that IN-defective HIV-1 failed
to initiate reverse transcription efficiently (66); as has
also been observed in
tat HIV-1, this function could be rescued by
supply of the missing protein in trans. Our data show that
the IN inhibitor RA can inhibit NERT. Although RA directly inhibited RT
in both ELISA and a NERT assay, experiments are in progress to
determine whether RA and IN interact with a common domain of RT.
In the present study, NERT-PCR assays discriminated between the
anti-initiation and antielongation effects on viral DNA synthesis of
PFA, ddATP, NVP, and RA and indicated that both NVP and RA directly
targeted very early reverse transcription in intact virions. In
addition, we describe for the first time a significant nonspecific component, whose mechanism of action is unknown, of the inhibition of
RT by NVP in NERT assays. The NERT-PCR method has distinct advantages
over in vitro systems in the testing of antiviral compounds, since all
of the cell-derived and viral factors and structural elements that
contribute to initiation are present in the intact virus. It seems
likely that novel compounds which target either RT or other components
of the RTIC could be identified and their activities could be optimized
using this strategy.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Sir Albert
Sakzewski Virus Research Centre, Royal Children's Hospital, Herston
Rd., Herston, Queensland, Australia 4029. Phone: (617) 3636-1679. Fax: (617) 3636-1401. E-mail:
d.harrich{at}mailbox.uq.edu.au.
Manuscript 125 from The Sir Albert Sakzewski Virus Research Centre.
 |
REFERENCES |
| 1.
|
Aiken, C., and D. Trono.
1995.
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.
J. Virol.
69:5048-5056[Abstract].
|
| 2.
|
Baltimore, D.
1970.
RNA-dependent DNA polymerase in virions of RNA tumour viruses.
Nature
226:1209-1211[CrossRef][Medline].
|
| 3.
|
Barat, C.,
V. Lullien,
O. Schatz,
G. Keith,
M. T. Nugeyre,
F. Gruninger-Leitch,
F. Barre-Sinoussi,
S. F. LeGrice, and J. L. Darlix.
1989.
HIV-1 reverse transcriptase specifically interacts with the anticodon domain of its cognate primer tRNA.
EMBO J.
8:3279-3285[Medline].
|
| 4.
|
Braddock, M.,
P. Cannon,
M. Muckenthaler,
A. J. Kingsman, and S. M. Kingsman.
1994.
Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences.
J. Virol.
68:25-33[Abstract/Free Full Text].
|
| 5.
|
Bukrinsky, M. I.,
N. Sharova,
T. L. McDonald,
T. Pushkarskaya,
W. G. Tarpley, and M. Stevenson.
1993.
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.
Proc. Natl. Acad. Sci. USA
90:6125-6129[Abstract/Free Full Text].
|
| 6.
|
Clever, J. L.,
D. A. Eckstein, and T. G. Parslow.
1999.
Genetic dissociation of the encapsidation and reverse transcription functions in the 5' R region of human immunodeficiency virus type 1.
J. Virol.
73:101-109[Abstract/Free Full Text].
|
| 7.
|
Crumpacker, C. S.
1992.
Mechanism of action of foscarnet against viral polymerases.
Am. J. Med.
92:3S-7S[Medline].
|
| 8.
|
Debyser, Z.,
A. M. Vandamme,
R. Pauwels,
M. Baba,
J. Desmyter, and E. De Clercq.
1992.
Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thione, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
J. Biol. Chem.
267:11769-11776[Abstract/Free Full Text].
|
| 9.
|
DeStefano, J. J.,
R. G. Buiser,
L. M. Mallaber,
P. J. Fay, and R. A. Bambara.
1992.
Parameters that influence processive synthesis and site-specific termination by human immunodeficiency virus reverse transcriptase on RNA and DNA templates.
Biochim. Biophys. Acta
1131:270-280[Medline].
|
| 10.
|
Dettenhofer, M.,
S. Cen,
B. A. Carlson,
L. Kleiman, and X. F. Yu.
2000.
Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription.
J. Virol.
74:8938-8945[Abstract/Free Full Text].
|
| 11.
|
Dornadula, G.,
S. Yang,
R. J. Pomerantz, and H. Zhang.
2000.
Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription.
J. Virol.
74:2594-2602[Abstract/Free Full Text].
|
| 12.
|
Goncalves, J.,
Y. Korin,
J. Zack, and D. Gabuzda.
1996.
Role of Vif in human immunodeficiency virus type 1 reverse transcription.
J. Virol.
70:8701-8709[Abstract].
|
| 13.
|
Gotte, M.,
X. Li, and M. A. Wainberg.
1999.
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction.
Arch. Biochem. Biophys.
365:199-210[CrossRef][Medline].
|
| 14.
|
Guo, J.,
L. E. Henderson,
J. Bess,
B. Kane, and J. G. Levin.
1997.
Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA.
J. Virol.
71:5178-5188[Abstract].
|
| 15.
|
Harrich, D.,
C. W. Hooker, and E. Parry.
2000.
The human immunodeficiency virus type 1 TAR RNA upper stem-loop plays distinct roles in reverse transcription and RNA packaging.
J. Virol.
74:5639-5646[Abstract/Free Full Text].
|
| 16.
|
Harrich, D.,
C. Hsu,
E. Race, and R. B. Gaynor.
1994.
Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants.
J. Virol.
68:5899-5910[Abstract/Free Full Text].
|
| 17.
|
Harrich, D.,
C. Ulich,
L. F. Garcia-Martinez, and R. B. Gaynor.
1997.
Tat is required for efficient HIV-1 reverse transcription.
EMBO J.
16:1224-1235[CrossRef][Medline].
|
| 18.
|
Harrison, G. P.,
M. S. Mayo,
E. Hunter, and A. M. Lever.
1998.
Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5' and 3' of the catalytic site.
Nucleic Acids Res.
26:3433-3442[Abstract/Free Full Text].
|
| 19.
|
Heinzinger, N. K.,
M. I. Bukinsky,
S. A. Haggerty,
A. M. Ragland,
V. Kewalramani,
M. A. Lee,
H. E. Gendelman,
L. Ratner,
M. Stevenson, and M. Emerman.
1994.
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
Proc. Natl. Acad. Sci. USA
91:7311-7315[Abstract/Free Full Text].
|
| 20.
|
Hsu, M. C.,
U. Dhingra,
J. V. Earley,
M. Holly,
D. Keith,
C. M. Nalin,
A. R. Richou,
A. D. Schutt,
S. Y. Tam,
M. J. Potash, et al.
1993.
Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro.
Proc. Natl. Acad. Sci. USA
90:6395-6399[Abstract/Free Full Text].
|
| 21.
|
Huang, Y.,
A. Khorchid,
J. Gabor,
J. Wang,
X. Li,
J. L. Darlix,
M. A. Wainberg, and L. Kleiman.
1998.
The role of nucleocapsid and U5 stem/A-rich loop sequences in tRNA(3Lys) genomic placement and initiation of reverse transcription in human immunodeficiency virus type 1.
J. Virol.
72:3907-3915[Abstract/Free Full Text].
|
| 22.
|
Huang, Y.,
J. Wang,
A. Shalom,
Z. Li,
A. Khorchid,
M. A. Wainberg, and L. Kleiman.
1997.
Primer tRNA3Lys on the viral genome exists in unextended and two-base extended forms within mature human immunodeficiency virus type 1.
J. Virol.
71:726-728[Abstract].
|
| 23.
|
Isel, C.,
C. Ehresmann,
G. Keith,
B. Ehresmann, and R. Marquet.
1995.
Initiation of reverse transcription of HIV-1: secondary structure of the HIV-1 RNA/tRNA(3Lys) (template/primer).
J. Mol. Biol.
247:236-250[CrossRef][Medline].
|
| 24.
|
Isel, C.,
J. M. Lanchy,
S. F. Le Grice,
C. Ehresmann,
B. Ehresmann, and R. Marquet.
1996.
Specific initiation and switch to elongation of human immunodeficiency virus type 1 reverse transcription require the post-transcriptional modifications of primer tRNA3Lys.
EMBO J.
15:917-924[Medline].
|
| 25.
|
Isel, C.,
R. Marquet,
G. Keith,
C. Ehresmann, and B. Ehresmann.
1993.
Modified nucleotides of tRNA(3Lys) modulate primer/template loop-loop interaction in the initiation complex of HIV-1 reverse transcription.
J. Biol. Chem.
268:25269-25272[Abstract/Free Full Text].
|
| 26.
|
Ji, X.,
G. J. Klarmann, and B. D. Preston.
1996.
Effect of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein on HIV-1 reverse transcriptase activity in vitro.
Biochemistry
35:132-143[CrossRef][Medline].
|
| 27.
|
Kerr, S. G., and K. S. Anderson.
1997.
RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates.
Biochemistry
36:14056-14063[CrossRef][Medline].
|
| 28.
|
Kiernan, R. E.,
A. Ono,
G. Englund, and E. O. Freed.
1998.
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.
J. Virol.
72:4116-4126[Abstract/Free Full Text].
|
| 29.
|
Klasens, B. I.,
H. T. Huthoff,
A. T. Das,
R. E. Jeeninga, and B. Berkhout.
1999.
The effect of template RNA structure on elongation by HIV-1 reverse transcriptase.
Biochim. Biophys. Acta
1444:355-370[Medline].
|
| 30.
|
Klaver, B., and B. Berkhout.
1994.
Premature strand transfer by the HIV-1 reverse transcriptase during strong-stop DNA synthesis.
Nucleic Acids Res.
22:137-144[Abstract/Free Full Text].
|
| 31.
|
Kohlstaedt, L. A., and T. A. Steitz.
1992.
Reverse transcriptase of human immunodeficiency virus can use either human tRNA(3Lys) or Escherichia coli tRNA(2Gln) as a primer in an in vitro primer-utilization assay.
Proc. Natl. Acad. Sci. USA
89:9652-9656[Abstract/Free Full Text].
|
| 32.
|
Kohlstaedt, L. A.,
J. Wang,
J. M. Friedman,
P. A. Rice, and T. A. Steitz.
1992.
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.
Science
256:1783-1790[Abstract/Free Full Text].
|
| 33.
|
Lanchy, J. M.,
C. Ehresmann,
S. F. Le Grice,
B. Ehresmann, and R. Marquet.
1996.
Binding and kinetic properties of HIV-1 reverse transcriptase markedly differ during initiation and elongation of reverse transcription.
EMBO J.
15:7178-7187[Medline].
|
| 34.
|
Lanchy, J. M.,
G. Keith,
S. F. Le Grice,
B. Ehresmann,
C. Ehresmann, and R. Marquet.
1998.
Contacts between reverse transcriptase and the primer strand govern the transition from initiation to elongation of HIV-1 reverse transcription.
J. Biol. Chem.
273:24425-24432[Abstract/Free Full Text].
|
| 35.
|
Lapadat-Tapolsky, M.,
H. De Rocquigny,
D. Van Gent,
B. Roques,
R. Plasterk, and J. L. Darlix.
1993.
Interactions between HIV-1 nucleocapsid protein and viral DNA may have important functions in the viral life cycle.
Nucleic Acids Res.
21:831-839[Abstract/Free Full Text]. (Erratum, 21:2024.)
|
| 36.
|
Li, X.,
Y. Quan,
E. J. Arts,
Z. Li,
B. D. Preston,
H. de Rocquigny,
B. P. Roques,
J. L. Darlix,
L. Kleiman,
M. A. Parniak, and M. A. Wainberg.
1996.
Human immunodeficiency virus type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site.
J. Virol.
70:4996-5004[Abstract/Free Full Text].
|
| 37.
|
Liang, C.,
L. Rong,
M. Gotte,
X. Li,
Y. Quan,
L. Kleiman, and M. A. Wainberg.
1998.
Mechanistic studies of early pausing events during initiation of HIV-1 reverse transcription.
J. Biol. Chem.
273:21309-21315[Abstract/Free Full Text].
|
| 38.
|
Lobel, L. I., and S. P. Goff.
1985.
Reverse transcription of retroviral genomes: mutations in the terminal repeat sequences.
J. Virol.
53:447-455[Abstract/Free Full Text].
|
| 39.
|
Lori, F.,
F. di Marzo Veronese,
A. L. de Vico,
P. Lusso,
M. S. Reitz, Jr., and R. C. Gallo.
1992.
Viral DNA carried by human immunodeficiency virus type 1 virions.
J. Virol.
66:5067-5074[Abstract/Free Full Text].
|
| 40.
|
Masuda, T.,
V. Planelles,
P. Krogstad, and I. S. Y. Chen.
1995.
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain.
J. Virol.
69:6687-6696[Abstract].
|
| 41.
|
Mazumder, A.,
N. Neamati,
S. Sunder,
J. Schulz,
H. Pertz,
E. Eich, and Y. Pommier.
1997.
Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action.
J. Med. Chem.
40:3057-3063[CrossRef][Medline].
|
| 42.
|
Nascimbeni, M.,
M. Bouyac,
F. Rey,
B. Spire, and F. Clavel.
1998.
The replicative impairment of Vif-mutants of human immunodeficiency virus type 1 correlates with an overall defect in viral DNA synthesis.
J. Gen. Virol.
79:1945-1950[Abstract].
|
| 43.
|
Oberg, B.
1989.
Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
Pharmacol. Ther.
40:213-285[CrossRef][Medline].
|
| 44.
|
Oude Essink, B. B.,
A. T. Das, and B. Berkhout.
1995.
Structural requirements for the binding of tRNA Lys3 to reverse transcriptase of the human immunodeficiency virus type 1.
J. Biol. Chem.
270:23867-23874[Abstract/Free Full Text].
|
| 45.
|
Quan, Y.,
Z. Gu,
X. Li,
Z. Li,
C. D. Morrow, and M. A. Wainberg.
1996.
Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of ( )2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1.
J. Virol.
70:5642-5645[Abstract/Free Full Text].
|
| 46.
|
Ramsey, C. A., and A. T. Panganiban.
1993.
Replication of the retroviral terminal repeat sequence during in vivo reverse transcription.
J. Virol.
67:4114-4121[Abstract/Free Full Text].
|
| 47.
|
Ren, J.,
R. Esnouf,
E. Garman,
D. Somers,
C. Ross,
I. Kirby,
J. Keeling,
G. Darby,
Y. Jones,
D. Stuart, et al.
1995.
High resolution structures of HIV-1 RT from four RT-inhibitor complexes.
Nat. Struct. Biol.
2:293-302[CrossRef][Medline].
|
| 48.
|
Rigourd, M.,
J. M. Lanchy,
S. F. Le Grice,
B. Ehresmann,
C. Ehresmann, and R. Marquet.
2000.
Inhibition of the initiation of HIV-1 reverse transcription by 3'-azido-3'-deoxythymidine. Comparison with elongation.
J. Biol. Chem.
275:26944-26951[Abstract/Free Full Text].
|
| 49.
|
Rong, L.,
C. Liang,
M. Hsu,
L. Kleiman,
P. Petitjean,
H. de Rocquigny,
B. P. Roques, and M. A. Wainberg.
1998.
Roles of the human immunodeficiency virus type 1 nucleocapsid protein in annealing and initiation versus elongation in reverse transcription of viral negative-strand strong-stop DNA.
J. Virol.
72:9353-9358[Abstract/Free Full Text].
|
| 50.
|
Schwartz, O.,
V. Marechal,
O. Danos, and J. M. Heard.
1995.
Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell.
J. Virol.
69:4053-4059[Abstract].
|
| 51.
|
Sova, P., and D. J. Volsky.
1993.
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1.
J. Virol.
67:6322-6326[Abstract/Free Full Text].
|
| 52.
|
Spence, R. A.,
K. S. Anderson, and K. A. Johnson.
1996.
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
Biochemistry
35:1054-1063[CrossRef][Medline].
|
| 53.
|
Spence, R. A.,
W. M. Kati,
K. S. Anderson, and K. A. Johnson.
1995.
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.
Science
267:988-993[Abstract/Free Full Text].
|
| 54.
|
Starcich, B.,
L. Ratner,
S. F. Josephs,
T. Okamoto,
R. C. Gallo, and F. Wong-Staal.
1985.
Characterization of long terminal repeat sequences of HTLV-III.
Science
227:538-540[Abstract/Free Full Text].
|
| 55.
|
Suo, Z., and K. A. Johnson.
1997.
Effect of RNA secondary structure on the kinetics of DNA synthesis catalyzed by HIV-1 reverse transcriptase.
Biochemistry
36:12459-12467[CrossRef][Medline].
|
| 56.
|
Temin, H. M., and S. Mizutani.
1970.
RNA-dependent DNA polymerase in virions of Rous sarcoma virus.
Nature
226:1211-1213[CrossRef][Medline].
|
| 57.
|
Thrall, S. H.,
R. Krebs,
B. M. Wohrl,
L. Cellai,
R. S. Goody, and T. Restle.
1998.
Pre-steady-state kinetic characterization of RNA-primed initiation of transcription by HIV-1 reverse transcriptase and analysis of the transition to a processive DNA-primed polymerization mode.
Biochemistry
37:13349-13358[CrossRef][Medline].
|
| 58.
|
Trono, D.
1992.
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses.
J. Virol.
66:4893-4900[Abstract/Free Full Text].
|
| 59.
|
Tsurutani, N.,
M. Kubo,
Y. Maeda,
T. Ohashi,
N. Yamamoto,
M. Kannagi, and T. Masuda.
2000.
Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells.
J. Virol.
74:4795-4806[Abstract/Free Full Text].
|
| 60.
|
Ulich, C.,
A. Dunne,
E. Parry,
C. W. Hooker,
R. B. Gaynor, and D. Harrich.
1999.
Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription.
J. Virol.
73:2499-2508[Abstract/Free Full Text].
|
| 61.
|
von Schwedler, U.,
J. Song,
C. Aiken, and D. Trono.
1993.
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.
J. Virol.
67:4945-4955[Abstract/Free Full Text].
|
| 62.
|
Winzor, D., and W. Sawyer.
1995.
Quantitative characterization of ligand binding.
Wiley-Liss, Inc., New York, N.Y.
|
| 63.
|
Wohrl, B. M.,
R. Krebs,
R. S. Goody, and T. Restle.
1999.
Refined model for primer/template binding by HIV-1 reverse transcriptase: pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrate.
J. Mol. Biol.
292:333-344[CrossRef][Medline].
|
| 64.
|
Wu, W.,
B. M. Blumberg,
P. J. Fay, and R. A. Bambara.
1995.
Strand transfer mediated by human immunodeficiency virus reverse transcriptase in vitro is promoted by pausing and results in misincorporation.
J. Biol. Chem.
270:325-332[Abstract/Free Full Text].
|
| 65.
|
Wu, W.,
L. E. Henderson,
T. D. Copeland,
R. J. Gorelick,
W. J. Bosche,
A. Rein, and J. G. Levin.
1996.
Human immunodeficiency virus type 1 nucleocapsid protein reduces reverse transcriptase pausing at a secondary structure near the murine leukemia virus polypurine tract.
J. Virol.
70:7132-7142[Abstract/Free Full Text].
|
| 66.
|
Wu, X.,
H. Liu,
H. Xiao,
J. A. Conway,
E. Hehl,
G. V. Kalpana,
V. Prasad, and J. C. Kappes.
1999.
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex.
J. Virol.
73:2126-2135[Abstract/Free Full Text].
|
| 67.
|
Zhang, H.,
O. Bagasra,
M. Niikura,
B. J. Poiesz, and R. J. Pomerantz.
1994.
Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals.
J. Virol.
68:7591-7597[Abstract/Free Full Text].
|
| 68.
|
Zhang, H.,
G. Dornadula,
P. Alur,
M. A. Laughlin, and R. J. Pomerantz.
1996.
Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription.
Proc. Natl. Acad. Sci. USA
93:12519-12524[Abstract/Free Full Text].
|
| 69.
|
Zhang, H.,
G. Dornadula, and R. J. Pomerantz.
1996.
Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments: an important stage for viral infection of nondividing cells.
J. Virol.
70:2809-2824[Abstract].
|
| 70.
|
Zhang, H.,
G. Dornadula,
Y. Wu,
D. Havlir,
D. D. Richman, and R. J. Pomerantz.
1996.
Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo.
J. Virol.
70:628-634[Abstract].
|
| 71.
|
Zhang, H.,
R. J. Pomerantz,
G. Dornadula, and Y. Sun.
2000.
Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process.
J. Virol.
74:8252-8261[Abstract/Free Full Text].
|
Journal of Virology, April 2001, p. 3095-3104, Vol. 75, No. 7
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.7.3095-3104.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Aguiar, R. S., Costa, L. J., Pereira, H. S., Brindeiro, R. M., Tanuri, A.
(2007). Development of a New Methodology for Screening of Human Immunodeficiency Virus Type 1 Microbicides Based on Real-Time PCR Quantification. Antimicrob. Agents Chemother.
51: 638-644
[Abstract]
[Full Text]
-
Aguiar, R. S., Pereira, H. S., Costa, L. J., Brindeiro, R. M., Tanuri, A.
(2006). Gag-Pol bearing a reverse transcriptase drug-resistant mutation influences viral genomic RNA incorporation into human immunodeficiency virus type 1 particles. J. Gen. Virol.
87: 2669-2677
[Abstract]
[Full Text]
-
Apolloni, A., Hooker, C. W., Mak, J., Harrich, D.
(2003). Human Immunodeficiency Virus Type 1 Protease Regulation of Tat Activity Is Essential for Efficient Reverse Transcription and Replication. J. Virol.
77: 9912-9921
[Abstract]
[Full Text]
-
Hill, M. K., Hooker, C. W., Harrich, D., Crowe, S. M., Mak, J.
(2001). Gag-Pol Supplied in trans Is Efficiently Packaged and Supports Viral Function in Human Immunodeficiency Virus Type 1. J. Virol.
75: 6835-6840
[Abstract]
[Full Text]